Key result
Transcatheter mitral valve-in-valve implantation using a 25 mm Direct Flow bioprosthesis was technically feasible and safe, resulting in normal valve function with no paravalvular regurgitation and a low transmitral gradient of 4 mmHg.
Case Report (n=1)
No
Transcatheter mitral valve-in-valve implantation using the Direct Flow device via a transapical approach is technically feasible and safe in a high-risk patient with a degenerated bioprosthesis.
Single-case feasibility of transapical mitral valve-in-valve with Direct Flow; hypothesis-generating and should not yet change practice.
AIMS: Mitral valve reoperations due to failing bioprostheses, in patients affected by multiple comorbidities, are associated with high morbidity and mortality. Transcatheter techniques may evolve as complementary approaches to surgery in these patients at high risk for surgery. METHODS AND RESULTS: We describe a case of Direct Flow 25 mm transcatheter valve implantation as valve-in-valve in a degenerated mitral bioprosthesis through a transapical approach in a 63-year-old man affected by dilated cardiomyopathy. The patient was affected by Carpentier-Edwards 29 mm severe regurgitation. The 25 mm Direct Flow bioprosthesis was advanced through the mitral bioprosthesis into the left atrium and then positioned using the three independent positioning wires. Transoesophageal echocardiography evidenced normal Direct Flow function with no paravalvular regurgitation and a low transmitral gradient of 4 mmHg. CONCLUSIONS: Our successful experience, characterised by a Heart Team approach and multidisciplinary patient care, demonstrated the technical feasibility and procedural safety of Direct Flow valve-in-valve mitral implantation.
No takes yet. Share an insight, caveat, or question.
Bruschi et al. (2016) conducted a case report in Degenerated mitral bioprosthesis (n=1). Direct Flow transcatheter valve implantation was evaluated on Technical feasibility and procedural safety. Transcatheter mitral valve-in-valve implantation using a 25 mm Direct Flow bioprosthesis was technically feasible and safe, resulting in normal valve function with no paravalvular regurgitation and a low transmitral gradient of 4 mmHg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: